A&O Shearman advises lenders on record financing for ITM – radiopharmaceutical specialist secures up to USD262.5 million

The capital will be used to prepare for commercial readiness and potential market launch of the company’s lead candidate, n.c.a.177Lu-edotreotide (also known as ITM-11 or 177Lu-edotreotide). In addition, the company will continue to accelerate the development of its innovative targeted radiopharmaceutical pipeline and the scale-up of Actinium-225 manufacturing through its joint venture, Actineer.

In addition to Blue Owl as debt provider, certain prominent equity investors such as Temasek, Athos, Blackrock, Qatar Investments, and Carbyne are involved. A&O Shearman provided comprehensive advice to the lenders on aspects of German law.

The A&O Shearman team was led by partner Dr. Rauni Ahammer and included associates Dr. Georg Lütkenhaus and Lennart Matzky (all Debt Finance, all Munich). The team was supported by counsel Eda Zhuleku (Medical Law), partner Dr. Alexander Veith, senior associate Dr. Maximilian Schmitt (both Corporate), associate Florian Preinfalk (Medical Law), partner Dr. Josef Parzinger (Restructuring, all Munich), as well as partner Dr. Heike Weber and associate Niklas Kniess (both Tax, both Frankfurt), partner Dr. Udo Olgemöller, Senior Associate Stephan Bühner, and Associate Nils Najmann (all Public Law, all Frankfurt).